Revalesio key facts
as of Oct 2026- Developer of an anti-inflammatory therapeutic drug designed to treat a variety of neurological diseases.
- Revalesio is valued at approximately $86.4M as of Oct 2026 (last reported valuation).
- It has raised $112.8M across 6 recorded rounds; the latest was Early Stage VC ($38.9M) in May 2022.
- Notable investors include Cumming Capital Management, ALS.
- Revalesio has filed 7 Form Ds with the SEC since 2012, most recently Apr 2024 ($25.5M sold to 31 investors).
- Status: Privately Held (backing).
Revalesio's last reported valuation, Jul 2020. Nothing priced has surfaced since.
- ·Watch Revalesio: the Monday email on marks, rounds and moves
Revalesio funding rounds
6 roundsWho backs Revalesio
2Revalesio valuation
Revalesio's last reported valuation was $86.4 million in Jul 2020. No priced round, secondary trade or fund mark has surfaced since.
How much has Revalesio raised?
Revalesio has raised $113 million across 6 recorded rounds since 2012. The largest was a $6 million early-stage round in Jun 2018; the most recent was a $38.9 million early-stage round in May 2022.
Revalesio has filed 7 Form Ds with the SEC since 2012, most recently in Apr 2024 ($25.5 million sold to 31 investors).
Revalesio investors
2 investors are on record for Revalesio, including Cumming Capital Management and ALS. The early-stage round in May 2022 drew 31 investors.
About Revalesio
Developer of an anti-inflammatory therapeutic drug designed to treat a variety of neurological diseases. The company's drug targets mitochondrial dysfunction and inflammation by combining intense local turbulence to provide neuroprotection through large energy dissipation rates and surface-to-volume mixing ratios, enabling physicians to treat amyotrophic lateral sclerosis and multiple sclerosis by slowing down disease progression and improving quality of life.
- Sector
- Healthcare
- HQ
- Tacoma, WA, United States
- Founded
- 2000
- Employees
- 21
- Website
- revalesio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.